Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This study is a single-center phase II randomized clinical trial to enroll low-risk breast cancer treat with breast-conserving surgery. All eligible patients are randomized to receive either ABPI (40Gy/10fx/2wks) or WBI(43.5Gy/15fx/3wks). Intensity modulated radiation therapy (IMRT) technique is used. Grade 2 or more acute and late toxicities are prospectively evaluated and compared.
Age
45–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Life Expectation: \> 5 years
Enrollment date no more than 12 weeks after breast-conserving surgery or no more than 8 weeks after adjuvant chemotherapy
Histologically confirmed diagnosis of invasive ductal carcinoma (grade 1-2), or mucinous carcinoma, or papillary carcinoma, or tubular carcinoma, or medullary carcinoma: primary tumor ≤ 3.0cm in maximum diameter and pN0; or histologically confirmed DCIS: primary tumor ≤ 2.5cm in maximum diameter, low-medium grade
Unifocal tumour (confirmed by diagnostic MRI)
No lymphovascular invasion
ER positive (defined as medium-strongly nuclear staining in \>1% of the cancer cells)
Negative radial resection margins of \>= 2 mm
Surgical clips placed in the tumor bed
Written informed consent.
You may not be if
Stage Ⅱ-Ⅲ
Multifocal tumors
Histologically confirmed diagnosis of invasive ductal carcinoma (grade 3), - - - invasive micropapillary carcinoma, carcinoma of lobular in situ, invasive - - - lobular carcinoma
Paget's disease of the nipple
Underwent oncoplastic surgery of ipsilateral breast
Underwent neoadjuvant chemotherapy or hormonal therapy
Previous or simultaneous contralateral breast cancer
